In:
British Journal of Haematology, Wiley, Vol. 166, No. 4 ( 2014-08), p. 540-549
Abstract:
The KMT 2E ( MLL 5 ) gene encodes a histone methyltransferase implicated in the positive control of genes related to haematopoiesis. Its close relationship with retinoic acid–induced granulopoiesis suggests that the deregulated expression of KMT 2E might lead acute promyelocytic leukaemia ( APL ) blasts to become less susceptible to the conventional treatment protocols. Here, we assessed the impact of KMT 2E expression on the prognosis of 121 APL patients treated with ATRA and anthracycline‐based chemotherapy. Univariate analysis showed that complete remission ( P = 0·006), 2‐year overall survival ( OS ) ( P = 0·005) and 2‐year disease‐free survival ( DFS ) rates ( P = 0·037) were significantly lower in patients with low KMT 2E expression; additionally, the 2‐year cumulative incidence of relapse was higher in patients with low KMT 2E expression ( P = 0·04). Multivariate analysis revealed that low KMT 2E expression was independently associated with lower remission rate (odds ratio [ OR ]: 7·18, 95% confidence interval [ CI ]: 1·71–30·1; P = 0·007) and shorter OS (hazard ratio [ HR ]: 0·27, 95% CI : 0·08–0·87; P = 0·029). Evaluated as a continuous variable, KMT 2E expression retained association with poor remission rate ( OR : 10·3, 95% CI : 2·49–43·2; P = 0·001) and shorter survival ( HR : 0·17, 95% IC : 0·05–0·53; P = 0·002), while the association with DFS was of marginal significance ( HR : 1·01; 95% CI : 0·99–1·02; P = 0·06). In summary, low KMT 2E expression may predict poor outcome in APL patients.
Type of Medium:
Online Resource
ISSN:
0007-1048
,
1365-2141
DOI:
10.1111/bjh.2014.166.issue-4
Language:
English
Publisher:
Wiley
Publication Date:
2014
detail.hit.zdb_id:
1475751-5
Permalink